Symbols

BIAF

bioAffinity·NASDAQ

--(--)

BIAF Profile

Bioaffinity Technologies, Inc.

A company that develops proprietary noninvasive diagnostic tests and cancer therapeutics to diagnose early-stage cancer

Industry

Healthcare Equipment and Supplies

Established Date

03/26/2014

Listing Date

09/01/2022

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.bioaffinitytech.com

Security Type

Common stock

Office address

3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217

Business

Introduction

BioAffinity Technologies, Inc., was incorporated as a Delaware corporation on March 26, 2014. The company develops non-invasive diagnostic tests that use flow cytometry and artificial intelligence-driven analysis for early-stage lung cancer and other respiratory diseases. Its main commercial testing product, CyPath Lung, is offered through its CAP-accredited laboratory subsidiary and is also advancing therapeutic research for cancer treatment.